Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effimia cycle control and tolerability study in women needing contraception in Italy
2024-519403-10-00Phase 4Authorised
- Sponsor
- Italfarmaco
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of norgestimate + ethinyl estradiol, norgestimate and ethinyl estradiol, sponsored by Italfarmaco. Primary endpoint: Intermenstrual spotting occurrence rate at cycle 6. Planned start Feb 2025; status: authorised.
02
Drugs
norgestimate + ethinyl estradiolnorgestimateethinyl estradiol
Beyond the preview
Go deeper on 2024-519403-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519403-10-00.